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Background: Studies about associations of infections with herpes viruses and other pathogens, such as Chlamydia
pneumoniae (CP) and Helicobacter pylori (HP) with cardiovascular disease (CVD), diabetes mellitus (DM), frailty and/or
mortality are conflicting. Since high levels of antibodies against these pathogens occur in the elderly, the role of
these pathogens in morbidity and mortality of vulnerable elderly was explored.
Results: Blood samples of 295 community dwelling psycho-geriatric patients were tested for IgG antibodies to
herpes simplex virus type 1 and 2, varicella zoster virus, Epstein Barr virus (EBV), cytomegalovirus (CMV), human
herpes virus type 6 (HHV6), CP and HP. Frailty was defined with an easy-to-use previously described frailty risk score.
Relative risks (RR) with 95% confidence intervals were calculated to evaluate associations between CVD, DM, frailty
and pathogens. Pathogens as a predictor for subsequent mortality were tested using Kaplan Meier analyses and
Cox proportional hazard models. The mean age was 78 (SD: 6.7) years, 20% died, 44% were defined as frail, 20%
had DM and 49% had CVD. Presence of CMV antibody titers was associated with frailty, as shown by using both
qualitative and quantitative tests, RR ratio 1.4 (95% CI: 1.003-2.16) and RR ratio 1.5 (95% CI: 1.06-2.30), respectively.
High IgG antibody titers of HHV6 and EBV were associated with DM, RR ratio 3.3 (95% CI: 1.57-6.49). None of the
single or combined pathogens were significantly associated with mortality and/or CVD.
Conclusions: Prior CMV infection is associated with frailty, which could be in line with the concept that CMV might
have an important role in immunosenescence, while high IgG titers of HHV6 and EBV are associated with DM. No
association between a high pathogen burden and morbidity and/or mortality could be demonstrated.
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Age related frailty and chronic diseases, such as diabetes
mellitus (DM) and cardiovascular disease (CVD) will in-
crease in developed countries, as the number of elderly
people in the developed countries is increasing. A quarter
of the population in most European countries will be above
65 years in the near future [1]. The pathophysiological
mechanisms of ageing and frailty and the exact causal
mechanisms of DM and CVD are not completely under-
stood. Chronic inflammation and prior infections with her-
pes viruses, Chlamydia pneumonia (CP) and Helicobacter
pylori (HP) are suggested to play a role in ageing, frailty,
DM and CVD [2-7].
Ageing is associated with deleterious changes in the
immune system called immune senescence which have
been observed in all mammals studies thus far [8]. Per-
sistent cytomegalovirus (CMV) infections, but no other
herpes virus infections have been found to increase
immunosenescence [8]. For instance, progressive accu-
mulation of CD 8+ T-cells is correlated with seropositi-
vity to CMV infection [9-12]. It has been hypothesized
that accumulation of CD8+ T-cells against one virus re-
duces the immunity to other pathogens [13,14] which is
illustrated by the association of CMV seropositivity with
non-responsiveness to anti-influenza vaccination [15].
Furthermore, chronic stimulation of the immune system
by CMV may lead to an increasing prevalence of senes-
cent dysfunctional T cells thereby contributing to mortal-
ity and frailty [5,14]. Also, Epstein-Barr virus (EBV) has
been associated with a remarkable accumulation of EBV
specific CD8 T-cells of up to 30% [13,14].
Some seroepidemiological studies have shown associa-
tions between infections with herpes viruses and other
common pathogens such as CP and HP on one side and
on the other side DM, atherosclerosis, dementia, cognitive
impairment, and frailty [2-7]. The exact causal mecha-
nisms are not yet known, although chronic inflammation,
which is a risk factor for DM type 2 [16], has been hypoth-
esized to be caused by the presence of persistent infection.
Indeed, CMV, varicella zoster virus (VZV) and herpes
simplex virus (HSV) have been associated with the occur-
rence of DM in some studies [6,17-19], but other studies
could not confirm this association with DM [20]. Simi-
larly, herpes viruses, HP and CP infections have been as-
sociated with atherosclerosis and CVD [2,7], whereas
others could not confirm these findings [21,22].
Overall, the concept of accelerating immunosene-
scence by persistent infections and subsequent increased
mortality and morbidity has been suggested in some
studies. The aim of this study is to determine associa-
tions between frailty, CVD, DM and mortality with single
pathogens and combined pathogen burden among pro-
spectively followed community dwelling psycho-geriatric
patients.Results
Pathogens and morbidity
A total of 295 blood samples were collected from commu-
nity dwelling psycho-geriatric patients between October
2002 and December 2005. The mean age of these patients
was 78.0 years ± 6.7 years and 64% (n = 188) were female.
The median follow-up period of the surviving patients was
25 months (range: 12–36 months). Forty four percent (n =
131/295) of the patients were considered frail, 20% (n = 59/
295) had DM (all patients had DM type 2) and 48% (n =
143/295) with CVD. Twenty percent of the 295 patients
(n = 60) died during the study period of 36 months. Fre-
quencies for single pathogens and pathogen burden are
shown in Table 1. VZV and EBV seronegative patients were
very small, only 3 and 4 patients respectively. Additionally,
46% (n = 136) were positive for all herpes viruses tested.
None of the single pathogens were significantly associ-
ated with CVD, but an association between seropositivity
for CMV and frailty (Tables 1 and 2) and association be-
tween high human herpes virus type 6 (HHV6) and high
EBV antibody titers and DM was observed (Table 3). Nei-
ther the total herpes burden (data not shown), nor the
pathogen burden (Table 1) was significantly associated
with CVD, DM and/or frailty. Additionally, CMV avidity
was not associated with CVD or DM.
Pathogens and mortality
Seropositivity of single pathogens was associated with
increased relative risks (RR) of mortality, but these results
did not reach statistical significance (Table 4). After
adjustment for frailty most relative risks decreased. Al-
most all patients (Table 1) were seropositive for VZV and
EBV. Therefore, VZV and EBV were left out Table 4.
CMV seropositivity and frailty
Of 295 patients, 67 were CMV IgG negative both by
AxSYM and DSX™. Two hundred and twenty six patients
were CMV IgG positive both by AxSYM and DSX™. Dis-
cordance was limited to 2 weakly positive results for DSX™
(44.20 U/ml and 49.10 U/ml) and negative results for
AxSYM (0.80 AU/ml and 2.10 AU/ml), confirmed by nega-
tive results with Vidas, low CMV IgG avidity and/or CMV
IgM negative results by DSX™ and considered negative.
Overall, 76.6% (n = 226) of the geriatric patients was
CMV IgG seropositive. Only 1 patient was CMV IgM sero-
positive with low value. CMV was associated with frailty,
RR 1.4 (95% CI: 1.003-2.16) and the quantitative tests
showed that the highest CMV IgG titers were more often
found in the frailty group RR 1.5 (95% CI: 1.06-2.30), see
Table 2. Mean CMV avidity was high 76.2% (SD = 7.9).
Herpesviruses and DM
HHV6 IgG was associated with DM RR 1.7 (95% CI:
0.96-3.13). The quantitative tests demonstrated that high
Table 1 Frequencies for pathogens and the associations between the different pathogens, cardiovascular disease
(CVD), diabetes mellitus (DM) and frailty
Serology test Range of test Median (IQR) Total DM+ CVD+ Frail+
(U/ml) Titer (U/ml) number(%) (n = 59) (n = 143) (n = 131)
HSVa IgG positive 30-2000 437 (389–484) 275 (93%) 57 (97%) 133 (93%) 122 (93%)
HSVa IgG negative - 20 (7%) 2 (3%) 10 (7%) 9 (7%)
VZVa IgG positive 100-2000 994 (612–1403) 292 (99%) 59 (100%) 141 (99%) 128 (98%)
VZVa IgG negative - 3 (1%) 0 (0%) 2 (1%) 3 (2%)
EBVa IgG positive 11-200 200 (130–200) 291 (99)% 58 (98%) 141 (99%) 128 (98%)
EBVa IgG negative - 4 (1%) 1 (2%) 2 (1%) 3 (2%)
CMVa IgG positive 226 (77%) 46 (78%) 115 (80%) 108 (82%)b
• AxSYM 15-250 250 (192–250)
• DSXTM 40-2000 373 (290–463)
CMVa IgG negative - 69 (23%) 13 (22%) 28 (20%) 23 (18%)b
HHV6a IgG positive >1.1 1.67 (1.37-2.34) 193 (65%) 45 (76%)c 97 (68%) 90 (69%)
HHV6a IgG negative - 102 (35%) 14 (24%)c 46 (32%) 41 (31%)
CPa IgG positive 45-270 81 (59–116) 150 (51%) 28 (47%) 74 (52%) 68 (52%)
CPa IgG negative - 144 (49%) 31 (53%) 69 (48%) 63 (48%)
HPa IgG positive 20-650 97 (36–211) 173 (59%) 32 (54%) 82 (47%) 77 (59%)
HPa IgG negative - 121 (41%) 27 (46%) 61 (43%) 54 (41%)
Pathogen burdend -
● Pathogen burden ≤ 4 53 (18%) 9 (15%) 25 (18%) 18 (14%)
● Pathogen burden = 5 - 95 (32%) 18 (31%) 46 (32%) 44 (33%)
● Pathogen burden = 6 - 103 (35%) 23 (39%) 46 (32%) 48 (37%)
● Pathogen burden = 7 - 44 (15%) 9 (15%) 26 (18%) 21 (16%)
aHSV: herpes simplex virus, VZV: varicella zoster virus, CMV: cytomegalovirus, EBV: Epstein-Barr virus, HHV6: human herpes virus type 6, CP: Chlamydia pneumonia,
HP: Helicobacter pylori.
bRR 1.4 (95% CI: 1.003-2.16).
cRR 1.7 (95% CI: 0.96-3.13).
dPathogen burden: number of IgG seropositive pathogens (HSV, VZV, EBV, CMV, HHV6, CP, HP).
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and high EBV antibody titers RR 1.7 (95% CI: 1.04-2.91)
were associated with DM, Table 3. An additional effect is
demonstrated when high HHV6 antibody titers and high
EBV antibody titers are combined RR 3.3 (95% CI: 1.57-
6.49), Table 3. Antibody titers of HSV, VZV, CMV, CP
and HP were not associated with DM.Table 2 Association between frailty and cytomegalovirus (CM
Test CMV result N
AxSYM CMV titer: <15 AU/ml 69
CMV titer: 15–192 AU/ml 55
CMV titer: ≥192 AU/ml 169
DSX™ CMV titer: <40 U/ml 67
CMV titer: 40–290 U/ml 56
CMV titer: ≥290 U/ml 172Discussion
Prior infections with herpes viruses, HP and CP are
reported to be associated with mortality and morbidity (i.e.
CVD, DM and frailty), although the results of different
studies are often conflicting [2-7,20-22]. Here, 8 pathogens
were tested both qualitative and quantitative in geriatric
patients. No robust association between the pathogenV) IgG titer (AxSYM and DSX™)
Frailty + Frailty – RR (95% CI)
(n = 131) (n = 164)
23 (17.5%) 46 (28.4%)
22 (17.0%) 33 (20.4%) 1.2 (0.71-2.00)
86 (65.5%) 83 (51.2%) 1.5 (1.06-2.30)
22 (16.8%) 45 (27.44%)
22 (16.8%) 34 (20.73%) 1.2 (0.72-2.03)
87 (66.4%) 85 (51.83%) 1.5 (1.06-2.35)
Table 3 Association between diabetes mellitus (DM) and antibody titers to human herpes virus (HHV6) and
epstein-barr virus (EBV)
Test result N DM + DM – RR ratio (95% CI)
(n = 59) (n = 236)
HHV6
• HHV6 titer: <1.1 103 14 (23.7%) 89 (37.7%)
• HHV6 titer: 1.1-2.3 144 27 (45.8%) 117 (49.6%) 1.38 (0.74-2.66)
• HHV6 titer: >2.3 48 18 (30.5%) 30 (12.7%) 2.76 (1.42-5.36)
EBV
• EBV titer: 0–200 U/ml 144 21 (35.6%) 123 (52.1%)
• EBV titer: ≥200 U/ml 151 38 (64.4%) 113 (47.9%) 1.73 (1.04-2.91)
HHV6 and EBV
• HHV6 titer <1.1 and EBV titer 0-200 127 15 (25.4%) 112 (47.5%)
• HHV6 titer 1.1-2.3 and EBV titer > =200 or HHV6 titer >2.3 and EBV titer 0-200 137 32 (54.2%) 105 (44.5%) 2.28 (1.1-4.7)
• HHV6 titer >2.3 and EBV titer > =200 31 12 (20.4%) 19 (8.0%) 3.28 (1.57-6.49)
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thogens showed increased relative risks with mortality. No
associations were found between single pathogens or com-
bined pathogens and CVD. DM was associated with two
herpes viruses, i.e. HHV6 and EBV, and an association was
demonstrated between frailty and CMV.
The association between CMV and frailty was also
found by Schmaltz et al. [5]. Whereas Schmaltz et al.
reported an association between CMV and frailty in 724
community dwelling women [5], we demonstrated this as-
sociation in both men and women. Furthermore, we have
performed at least 2 quantitative tests for CMV IgG, a
quantitative test for CMV IgM and a test for CMV avidity
in order to obtain a more complete CMV serology status.
The highest CMV IgG titers were found in frail older
people and suggest a dose–response relation, as elevated
IgG titers to CMV among seropositive non-immuno-
compromised individuals suggest frequent viral reacti-
vations [23]. No significant association between CMV (and
other pathogens) and mortality was found. Power may be
too low to show effects of CMV on mortality. The causal
mechanism of the association between CMV and frailty isTable 4 Unadjusted and adjusted mortality hazard ratios
for frailty with 95% confidence intervals
Unadjusted RR (95% CI) Adjusted for frailty RR (95% CI)
HSVa 1.23 (0.38-3.93) 1.24 (0.39-3.96)
CMVb 1.60 (0.81-3.15) 1.20 (0.61-2.39)
HHV6c 1.00 (0.59-1.71) 0.88 (0.5-1.49)
CPd 1.07 (0.64-1.77) 1.06 (0.64-1.76)
HPe 1.26 (0.75-2.13) 1.24 (0.73-2.09)
aHSV: herpes simplex virus.
bCMV: cytomegalovirus.
cHHV6: human herpes virus type 6.
dCP: Chlamydia pneumonia.
eHP: Helicobacter pylori.not yet clear. The association between CMV and frailty
could be in line with the concept that CMV might have an
important role in immunosenescence [8]. Understanding
the role of CMV in the immunosenescence hypothesis
more clearly may elucidate the association between CMV
and frailty. Therefore, it would be interesting to investigate
alterations in the immune system, such as CD4/CD8 ra-
tio’s, in these frail patients. Taken together, an association
between CMV and frailty was found.
A recent study showed that in the above 85 year olds
CMV seropositivity was higher in patients with DM [19],
unfortunately no other pathogens were determined in that
study. In our study the CMV seropositivity was only
slightly higher in patients with DM. However, DM type 2
was related to the presence of high EBV IgG titers and
high HHV6 response. Two case reports have described
the development of a type 1 DM with HHV6 reactivation
[24,25] and two other case reports during an acute EBV
infection [26,27]. Reactivations of both viruses could play
a role in DM and in the chronic systemic inflammation in
DM [3,6,24,25], since high EBV IgG titers and a high
HHV6 response suggests reactivation [28,29]. It is unlikely
that the presence of DM has resulted in increased anti-
HHV6 or EBV antibody titers since anti-viral antibody
levels are decreased rather than increased in patients with
DM [18,30]. However, little is known about possible
causative mechanisms and more evidence is needed to
support this association.
One of the strengths of this study is the large number of
pathogens that have been studied in this well defined pro-
spectively followed elderly people group. High antibody ti-
ters, together with a high CMV avidity in all CMV positive
patients indicate non-primary past or recurrent infection
[31]. Antibody titers have been useful to study the dose–
response relation. In future research measuring a combin-
ation of humoral and cellular immunity markers and
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be valuable for revealing the role of herpes viruses in mor-
tality and morbidity, especially frailty and DM. Under-
standing the role of CMV in the immunosenescence
hypothesis more clearly may elucidate the association be-
tween CMV and frailty.
Conclusion
Of the 8 pathogens studied in this community dwelling
psycho-geriatric patients associations have been shown
between prior CMV infection and frailty, which could be
in line with the concept that CMV might have an import-
ant role in immunosenescence and an association between
DM and prior infection with HHV6 and EBV was demon-
strated. We could not demonstrate an association between
a high pathogen burden and morbidity and/or mortality.
Methods
Study population
Data from a study with community dwelling psycho-
geriatric patients attending the Diagnostic Observation
Centre for Psycho Geriatric patients of the Maastricht
University Medical Centre between October 2002 and
December 2005 were used. For all patients the frailty
score, the presence of DM and that of CVD was deter-
mined, and blood samples were collected when patients
were included. Frailty was defined with an easy-to-use
previously described frailty risk score [32]. The frailty
score was calculated with the following rule: Age (per
10 years) x 4 + male sex x 10 + no partner x 5 + BMI <
18.5 kg/m2 + cardiovascular disease x 4 + ADL process
deficit x 7. The mean of the frailty score was 52 (median:
51, range: 28–76). The cut-off for frailty was set on ≥53
points” [32].
DM was defined as a history of DM or an elevated
fasting glucose and increased HBA1c. CVD in this study
was defined from hypertension to severe CVD. Patients
were prospectively followed for 36 months.
This study was approved by the medical ethical commit-
tee of the Maastricht University Medical Centre. Written
informed consent was obtained from the patient for the
publication of this report and any accompanying images.
Laboratory techniques
The blood samples were stored as plasma at –80°C. All
blood samples were tested for immunoglobulin G (IgG) to
detect antibodies to HSV type 1 and 2, VZV, EBV (Virion\
Serion, Würzberg, Germany), CMV (AxSYM, Abbott la-
boratories, Abbott Park, USA and Virion\Serion, Würzberg
and in case of discordance also Vidas, BioMérieux Marcy
l’Etoile, France), HHV6 (Panbio diagnostics, Grenoble,
France), HP (Orion Diagnostica, Espoo, Finland) and to
CP (Anilabsystems Ltd., Vantaa, Finland). Additionally,
immunoglobulin M (IgM) and CMV IgG avidity (Virion\Serion, Würzberg, Germany) were tested. All antibodies
were tested with quantitative enzyme immunoassay (EIA)
on the DSX™ Fourplate Automated Elisa processing
system, Chantilly, USA. HSV IgG was positive if anti-
bodies were between 30 and 2000 U/ml, VZV IgG 100–
2000 U/ml, EBV IgG 11–200 U/ml, CMV IgG AxSYM
15–250 AU/ml, CMV IgG Dynex 40–2000 U/ml, HHV6
IgG >1.1, CP IgG 45–270 U/ml and HP IgG 20–
650 U/ml. Further classification of the CMV, EBV and
HHV6 titers were made in weakly positive and strongly
positive based on the interquartile range. For CMV the lower
quartile (AxSYM: <192 AU/ml and DSX™: <290 U/ml)
was considered weakly positive and the quartiles above
192 AU/ml (AxSYM) and above 290 U/ml (DSX™) as
strongly positive. For EBV the quartiles below 200 U/ml
were considered weakly positive and the quartiles ≥
200 U/ml were considered strongly positive. For HHV6
the highest quartile (≥2.3 U/ml) was considered strongly
positive and the quartiles lower than 2.3 U/ml as weakly
positive. All tests were performed according to the manu-
factures’ instructions.
Statistical analysis
Prevalence rates were calculated for single infection, her-
pes burden (aggregated seropositivity to IgG antibodies
for HSV1-2, VZV, EBV, CMV and HHV6) and pathogen
burden (aggregated seropositivity to IgG antibodies for the
herpes burden, CP and HP). The associations between dis-
ease (CVD, DM) or frailty and seropositivity for pathogens
at baseline were expressed as relative risks with 95% confi-
dence intervals. Chi-square tests and analysis of variance
(ANOVA) were performed to test for statistical signifi-
cance. Kaplan Meier survival analysis and Cox propor-
tional hazard models were used to evaluate whether
seropositivity for pathogens is associated with higher risk
of subsequent mortality. Follow-up time was calculated
from the date of inclusion to the date of death or the date
of last follow-up (censoring date). Hazard ratios with 95%
confidence intervals (unadjusted and adjusted for frailty)
were calculated. A P-value of <0.05 was considered statis-
tically significant. Analyses were carried out with SPSS
16.0 (SPSS Inc., Chicago, USA).
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